According to the World Health Organization (WHO) reports that cancer is the second biggest cause of mortality globally, accounting for almost one in six fatalities. In 2020, cancer-related fatalities will account for close to 10 million deaths worldwide. The rising prevalence of paediatric cancer are also a significant factor anticipated to fuel market expansion. According to a WHO report, every year, 400,000 children between the ages of 0 and 19 are given cancer diagnoses. Additionally, it is projected that the market expansion will be aided by medical professionals using genetics in cancer treatment.
Frequently Asked Questions
The market is segmented based on Segmentation, By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Sequencing Technologies), Product (Consumables, Instrument, Others), Application (Diagnostics and Disease Profiling, Drug Discovery, Others) – Industry Trends and Forecast to 2032
.
The Global Tumor Transcriptomics Market size was valued at USD 9.63 USD Billion in 2024.
The Global Tumor Transcriptomics Market is projected to grow at a CAGR of 10.45% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
